Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-22-037027
Date:2022-06-13
Issuer: KINNATE BIOPHARMA INC. (KNTE)
Original Submission Date:

Reporting Person:

FLAHERTY KEITH T.
103 MONTGOMERY STREET, SUITE 150
THE PRESIDIO OF SAN FRANCISCO SAN FRANCISCO, CA 94129

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 8.38 2022-06-13 deemed execution date A 20,250 (a) 2032-06-13 common stock 20,250 $8.38 20,250 direct
Footnotes
IDfootnote
f1 1/12th of the shares underlying the option vest and become exercisable on a monthly basis starting july 13, 2022 (the vest base date) and thereafter on the same day of the month as the vest base date or if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the vest base date.

Elevate your investments